While the emergence of new antirheumatic agents—including biologics—has revolutionized the treatment of rheumatoid arthritis (RA), these drugs come a high cost to the healthcare system. Furthermore, many patients who receive these drugs may not respond to therapy, thereby increasing costs without improving outcomes.